Hypercortisolism Screening in Cardiology Practice

In ‘Hypercortisolism Screening in Cardiology Practice,’ our panel explores the evolving role of cardiologists in identifying patients at risk for hypercortisolism and initiating appropriate screening evaluations. Expert cardiology faculty discuss why hypercortisolism has historically been underrecognized in cardiovascular care and highlight the growing awareness of cortisol excess as a potential contributor to resistant hypertension and cardiometabolic disease.

The panel examines practical approaches to screening and reviews the biochemical tests commonly used to evaluate hypercortisolism. They discuss the strengths and limitations of available screening methods and consider how factors such as patient characteristics, testing logistics, and clinical context may influence interpretation of results. Throughout the conversation, the panelists emphasize that screening for hypercortisolism is often more straightforward and accessible than many clinicians may assume.

The expert faculty also explore the role of the dexamethasone suppression test and discuss how it may serve as an effective initial screening tool for patients with resistant hypertension or other clinical features suggestive of cortisol excess. They highlight the nuances of testing while recognizing that the first step is identifying patients who warrant evaluation.

The panel of experts underscores the collaborative nature of patient care and discusses how cardiologists can play a critical role in recognizing potential cases of hypercortisolism before referral for further evaluation and management. By increasing awareness of available screening tools and reinforcing the importance of early identification, the discussion provides practical insights that may help clinicians better incorporate hypercortisolism screening into routine cardiovascular practice.

Our next episode, ‘Guidelines and Barriers to Hypercortisolism Screening in Cardiology,’ explores how updated expert recommendations and emerging evidence are influencing the role of hypercortisolism screening in patients with resistant hypertension and cardiovascular disease. The panelists discuss practical barriers to implementation and strategies to improve awareness, identification, and evaluation of at-risk patients.